[go: up one dir, main page]

CL2014000395A1 - Compuestos derivados de piridazinona sustituida; compuesto intermediario; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de la esquizofrenia, trastorno esquizoafectivo, trastornos cognitivos o dolor. - Google Patents

Compuestos derivados de piridazinona sustituida; compuesto intermediario; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de la esquizofrenia, trastorno esquizoafectivo, trastornos cognitivos o dolor.

Info

Publication number
CL2014000395A1
CL2014000395A1 CL2014000395A CL2014000395A CL2014000395A1 CL 2014000395 A1 CL2014000395 A1 CL 2014000395A1 CL 2014000395 A CL2014000395 A CL 2014000395A CL 2014000395 A CL2014000395 A CL 2014000395A CL 2014000395 A1 CL2014000395 A1 CL 2014000395A1
Authority
CL
Chile
Prior art keywords
schizophrenia
pain
treatment
intermediate compound
cognitive disorders
Prior art date
Application number
CL2014000395A
Other languages
English (en)
Inventor
William Farnaby
Charlotte Fieldhouse
Katherine Hazel
Catrina Kerr
Natasha Kinsella
David Livermore
Kevin Merchant
David Miller
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1114399.7A external-priority patent/GB201114399D0/en
Priority claimed from GB201118658A external-priority patent/GB201118658D0/en
Priority claimed from GBGB1203533.3A external-priority patent/GB201203533D0/en
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CL2014000395A1 publication Critical patent/CL2014000395A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C07D237/16—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/18—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22—Nitrogen and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
CL2014000395A 2011-08-22 2014-02-17 Compuestos derivados de piridazinona sustituida; compuesto intermediario; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de la esquizofrenia, trastorno esquizoafectivo, trastornos cognitivos o dolor. CL2014000395A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1114399.7A GB201114399D0 (en) 2011-08-22 2011-08-22 Novel compounds
GB201118658A GB201118658D0 (en) 2011-10-27 2011-10-27 Novel compounds
GBGB1203533.3A GB201203533D0 (en) 2012-02-29 2012-02-29 Novel compounds

Publications (1)

Publication Number Publication Date
CL2014000395A1 true CL2014000395A1 (es) 2014-12-05

Family

ID=46758786

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014000395A CL2014000395A1 (es) 2011-08-22 2014-02-17 Compuestos derivados de piridazinona sustituida; compuesto intermediario; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de la esquizofrenia, trastorno esquizoafectivo, trastornos cognitivos o dolor.

Country Status (38)

Country Link
US (6) US9290456B2 (es)
EP (1) EP2748149B9 (es)
JP (1) JP6022573B2 (es)
KR (1) KR101961851B1 (es)
CN (1) CN103748079B (es)
AP (1) AP2014007512A0 (es)
AR (2) AR087607A1 (es)
AU (1) AU2012298335B2 (es)
BR (1) BR112014003906B1 (es)
CA (1) CA2846204C (es)
CL (1) CL2014000395A1 (es)
CO (1) CO6910197A2 (es)
CR (1) CR20140133A (es)
CY (1) CY1117105T1 (es)
DK (1) DK2748149T5 (es)
DO (1) DOP2014000036A (es)
EA (1) EA024956B1 (es)
EC (1) ECSP14013215A (es)
ES (1) ES2559631T3 (es)
GE (1) GEP20156372B (es)
HR (1) HRP20151310T2 (es)
HU (1) HUE026691T2 (es)
IL (1) IL230143A (es)
JO (1) JO3115B1 (es)
ME (1) ME02319B (es)
MX (1) MX2014000783A (es)
MY (1) MY180618A (es)
PE (1) PE20141208A1 (es)
PH (1) PH12014500405A1 (es)
PL (1) PL2748149T3 (es)
PT (1) PT2748149E (es)
RS (1) RS54515B9 (es)
SI (1) SI2748149T1 (es)
SM (1) SMT201600023B (es)
TW (1) TWI546289B (es)
UY (1) UY34280A (es)
WO (1) WO2013027000A1 (es)
ZA (1) ZA201400153B (es)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10189802B2 (en) 2008-11-07 2019-01-29 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
US10201618B2 (en) 2015-06-19 2019-02-12 Massachusetts Institute Of Technology Alkenyl substituted 2,5-piperazinediones, compositions, and uses thereof
US11458158B2 (en) 2011-10-27 2022-10-04 Massachusetts Institute Of Technology Amino acid-, peptide- and polypeptide-lipids, isomers, compositions, and uses thereof
US12390528B2 (en) 2011-03-28 2025-08-19 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
US9212147B2 (en) 2011-11-15 2015-12-15 Takeda Pharmaceutical Company Limited Dihydroxy aromatic heterocyclic compound
US9505753B2 (en) 2012-08-08 2016-11-29 The Johns Hopkins University Inhibitors of D-amino acid oxidase
GB201222711D0 (en) * 2012-12-17 2013-01-30 Takeda Pharmaceutical Novel compounds
US9956113B2 (en) 2013-03-12 2018-05-01 The Board Of Trustees Of The Leland Stanford Junior University Method and system for regulating core body temperature
GB201403944D0 (en) * 2014-03-06 2014-04-23 Takeda Pharmaceutical New use
KR20160147868A (ko) * 2014-04-30 2016-12-23 위펑 제인 쳉 D-아미노산 옥시다제 억제제로서 공지된 화합물의 용도
WO2019043635A1 (en) 2017-09-01 2019-03-07 Richter Gedeon Nyrt. COMPOUNDS INHIBITING THE ACTIVITY OF D-AMINO ACID OXIDASE
US10336724B2 (en) * 2017-10-18 2019-07-02 Syneurx International (Taiwan) Corp. D-amino acid oxidase inhibitors and therapeutic uses thereof
US12403034B2 (en) 2019-01-31 2025-09-02 Flotherm, Inc. Sleeve-based body temperature regulation
CN109725092A (zh) * 2019-03-19 2019-05-07 北京和合医学诊断技术股份有限公司 检测血液中齐拉西酮含量的液相色谱分析方法
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤
AU2022228417A1 (en) 2021-03-01 2023-10-26 Neurocrine Biosciences, Inc. Use of luvadaxistat for the treatment of cognitive impairment

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH636632A5 (de) 1976-10-08 1983-06-15 Ciba Geigy Ag Neues verfahren zur herstellung von schwermetallkomplexen.
LU75958A1 (es) 1976-10-08 1978-05-16
GB2025416A (en) 1978-07-14 1980-01-23 Pfizer Ltd Mercaptopyridazinethione antifungal agents
GB8421427D0 (en) 1984-08-23 1984-09-26 Smith Kline French Lab Chemical compounds
US4743685A (en) 1985-09-26 1988-05-10 E. R. Squibb & Sons, Inc. 2-oxo-1-[[(substituted sulfonyl)amino]carbonyl]azetidines
EG18314A (en) 1985-09-26 1993-02-28 Squibb & Sons Inc Process for preparing of 2-oxo-1((substituted sulfonyl)amino)carbonyl)-azitidines
DK170088A (da) 1987-04-10 1988-10-11 Hoffmann La Roche Acylderivater
WO1989000423A1 (en) 1987-07-09 1989-01-26 Pfizer Inc. 2-amino-5-hydroxy-4-pyrimidones
JPH01202875A (ja) 1988-02-09 1989-08-15 Fujitsu Ltd 超伝導材料構造の製造方法
US5244890A (en) 1988-06-06 1993-09-14 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
CA2020654A1 (en) 1989-07-07 1991-01-08 Yohko Akiyama Stabilized fgf composition and production thereof
ATE128006T1 (de) 1990-11-22 1995-10-15 Cerestar Holding Bv Verfahren zur herstellung von schokolade.
EP0544166A3 (en) 1991-11-26 1993-11-03 Hoffmann La Roche Cephalosporinderivatives
GB9219313D0 (en) 1992-09-11 1992-10-28 Kodak Ltd Method of forming a photographic colour image
EP0724573A1 (en) 1993-10-20 1996-08-07 PHARMACIA & UPJOHN COMPANY Pyrimidinones as antiarthritic and anti-inflammatories
PT777671E (pt) 1994-08-24 2000-08-31 Astrazeneca Ab Compostos espiro-azabiciclicos uteis em terapia
JPH092534A (ja) 1995-06-16 1997-01-07 Terada Seisakusho:Kk 茶貯蔵容器
JPH0925234A (ja) 1995-07-12 1997-01-28 Wakunaga Pharmaceut Co Ltd 脳疾患改善剤
SE9504661D0 (sv) 1995-12-22 1995-12-22 Astra Pharma Inc New compounds
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
AR013184A1 (es) 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
SE9702799D0 (sv) 1997-07-25 1997-07-25 Astra Ab New compounds
EP1007515A1 (en) 1997-08-22 2000-06-14 Abbott Laboratories Arylpyridazinones as prostaglandin endoperoxide h synthase biosynthesis inhibitors
US6525053B1 (en) 1997-08-22 2003-02-25 Abbott Laboratories Prostaglandin endoperoxide H synthase biosynthesis inhibitors
US6440965B1 (en) 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
DE69930624T2 (de) 1998-06-10 2006-09-14 Meiji Seika Kaisha Ltd. Arzneimittel für hinterstrangataxie und zusammensetzung zur behandlung von hinterstrangataxie
JP2003512292A (ja) 1998-10-27 2003-04-02 アボット・ラボラトリーズ プロスタグランジンエンドペルオキシドｈシンターゼ生合成阻害剤
SE9900100D0 (sv) 1999-01-15 1999-01-15 Astra Ab New compounds
SE9903760D0 (sv) 1999-10-18 1999-10-18 Astra Ab New compounds
SE9904176D0 (sv) 1999-11-18 1999-11-18 Astra Ab New use
SE0000540D0 (sv) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
JP2002028187A (ja) 2000-07-14 2002-01-29 Toto Ltd 車いす
SE0002729D0 (sv) 2000-07-20 2000-07-20 Astrazeneca Ab Novel compound form
WO2002020500A2 (en) 2000-09-01 2002-03-14 Icos Corporation Materials and methods to potentiate cancer treatment
CN101486683B (zh) * 2000-09-18 2011-12-21 卫材R&D管理有限公司 哒嗪酮和三嗪酮化合物及其作为药物制剂的用途
CA2433158C (en) 2000-12-28 2011-05-10 Shionogi & Co., Ltd. Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor
US7229994B2 (en) 2001-05-18 2007-06-12 Astrazeneca Ab 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain anxiety or gastrointestinal disorders
PT1397366E (pt) 2001-06-01 2007-04-30 Astrazeneca Ab Novo ligando para os receptores nicotínicos da acetilcolina úteis em terapia
WO2003047558A2 (en) 2001-12-03 2003-06-12 Genset S.A. Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors
JP4120586B2 (ja) 2002-01-18 2008-07-16 アステラス製薬株式会社 ２−アシルアミノチアゾール誘導体又はその塩
NZ561993A (en) 2002-04-18 2008-09-26 Astrazeneca Ab Spiroazabicyclic heterocyclic amines as potent ligands for nicotinic acetylcholine receptors
CN1325500C (zh) 2002-04-18 2007-07-11 阿斯特拉曾尼卡有限公司 呋喃基化合物
JP4511196B2 (ja) 2002-04-18 2010-07-28 アストラゼネカ・アクチエボラーグ チエニル化合物
AU2003245669A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain aromatic monocycles as kinase modulators
SE0202465D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab New compounds
SE0202430D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab New Compounds
SE0202598D0 (sv) 2002-09-02 2002-09-02 Astrazeneca Ab Alpha-7 Nicotinic receptor agonists and statins in combination
EP1620428A1 (en) 2003-04-23 2006-02-01 Pharmacia & Upjohn Company LLC Substituted pyrimidinones and pyrimidinthiones as crf antagonists
BRPI0416692A (pt) 2003-11-19 2007-01-30 Array Biopharma Inc inibidores heterocìclicos de mek e métodos de emprego destes
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
MY141255A (en) 2003-12-11 2010-03-31 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
AU2004312530A1 (en) * 2003-12-29 2005-07-21 Sepracor Inc. Pyrrole and pyrazole DAAO inhibitors
ES2332184T3 (es) 2004-03-22 2010-01-28 ELI LILLY & COMPANY Derivados de piridilo y su uso como antagonistas del receptor mglu5.
JP2008543781A (ja) 2005-06-10 2008-12-04 メモリー・ファーマシューティカルズ・コーポレイション ホスフオジエステラーゼ４阻害剤
TWI375669B (en) 2006-03-17 2012-11-01 Sumitomo Chemical Co Pyridazinone compound and use thereof
US7579370B2 (en) 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
BRPI0713216A2 (pt) * 2006-06-30 2012-12-04 Sepracor Inc inibiadores heterocìclos fundidos da d-aminoácido oxidase
KR20090111322A (ko) 2007-01-18 2009-10-26 세프라코 아이엔시. 디 아미노산 옥시다제의 억제제
AR064962A1 (es) 2007-01-22 2009-05-06 Syngenta Participations Ag Derivados de piridazina utiles como fungicidas
EP2586778A3 (en) 2007-03-15 2013-07-31 Merck Sharp & Dohme Corp. Pyridazinone derivatives useful as glucan synthase inhibitors
TWI404533B (zh) 2007-03-28 2013-08-11 Apotex Technologies Inc 去鐵酮（ｄｅｆｅｒｉｐｒｏｎｅ）之氟化衍生物
WO2008156607A1 (en) 2007-06-12 2008-12-24 Neurogen Corporation Substituted pyrimidinones
JP2009002534A (ja) 2007-06-19 2009-01-08 Denso Corp 熱交換器
WO2009142732A2 (en) 2008-05-20 2009-11-26 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
US20100120740A1 (en) 2008-08-07 2010-05-13 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
WO2010058314A1 (en) * 2008-11-18 2010-05-27 Pfizer Inc. Hydroxyquinolin-2(1h)-ones and derivatives thereof
ME02337B (me) 2009-02-05 2016-06-20 Takeda Pharmaceuticals Co Jedinjenja piridazinona
US20130065857A1 (en) 2009-10-12 2013-03-14 Baylor College Of Medicine Novel dxr inhibitors for antimicrobial therapy
PL2542084T3 (pl) 2010-03-04 2018-05-30 Merck Sharp & Dohme Corp. Inhibitory katecholo-O-metylotransferazy i ich zastosowanie w leczeniu zaburzeń psychotycznych
CA2789474A1 (en) 2010-03-04 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders
CA2789471C (en) 2010-03-04 2018-01-02 Merck Sharp & Dohme Corp. Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders
US20120046232A1 (en) 2010-06-22 2012-02-23 Medical University Of South Carolina Compositions and methods for reducing relapse of addictive behavior
AU2012275499A1 (en) 2011-06-27 2013-12-19 Kyorin Pharmaceutical Co., Ltd. Bridged bicyclic compounds for the treatment of bacterial infections
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
JP2013051513A (ja) 2011-08-30 2013-03-14 Minebea Co Ltd ダンパー及びそれを用いたスピーカ
US9212147B2 (en) 2011-11-15 2015-12-15 Takeda Pharmaceutical Company Limited Dihydroxy aromatic heterocyclic compound
US8868710B2 (en) 2011-11-18 2014-10-21 Amazon Technologies, Inc. Virtual network interface objects
GB201222711D0 (en) 2012-12-17 2013-01-30 Takeda Pharmaceutical Novel compounds
JP6364420B2 (ja) 2013-02-21 2018-07-25 武田薬品工業株式会社 ピリダジノン化合物の製造方法
GB201403944D0 (en) 2014-03-06 2014-04-23 Takeda Pharmaceutical New use
JP5897196B1 (ja) 2015-10-05 2016-03-30 大同化成工業株式会社 糖又は糖アルコール、膨潤型結合剤、崩壊剤及び高吸収性賦形剤を含む複合化造粒物及びその製造方法
EP3354283B1 (en) 2017-06-20 2019-08-07 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical capsule composition comprising silodosin
US10336724B2 (en) 2017-10-18 2019-07-02 Syneurx International (Taiwan) Corp. D-amino acid oxidase inhibitors and therapeutic uses thereof
US12370192B2 (en) 2019-09-16 2025-07-29 Takeda Pharmaceutical Company Limited Azole-fused pyridazin-3(2H)-one derivatives
AU2022228417A1 (en) 2021-03-01 2023-10-26 Neurocrine Biosciences, Inc. Use of luvadaxistat for the treatment of cognitive impairment

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10189802B2 (en) 2008-11-07 2019-01-29 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
US11414393B2 (en) 2008-11-07 2022-08-16 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
US12390528B2 (en) 2011-03-28 2025-08-19 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
US11458158B2 (en) 2011-10-27 2022-10-04 Massachusetts Institute Of Technology Amino acid-, peptide- and polypeptide-lipids, isomers, compositions, and uses thereof
US10201618B2 (en) 2015-06-19 2019-02-12 Massachusetts Institute Of Technology Alkenyl substituted 2,5-piperazinediones, compositions, and uses thereof

Also Published As

Publication number Publication date
JP2014524461A (ja) 2014-09-22
AR087607A1 (es) 2014-04-03
US20130052281A1 (en) 2013-02-28
US20150030704A1 (en) 2015-01-29
ECSP14013215A (es) 2014-05-31
EA201490471A1 (ru) 2014-05-30
BR112014003906B1 (pt) 2022-03-22
CR20140133A (es) 2014-06-05
SI2748149T1 (sl) 2016-02-29
US20170173007A1 (en) 2017-06-22
IL230143A (en) 2017-03-30
JP6022573B2 (ja) 2016-11-09
WO2013027000A1 (en) 2013-02-28
TW201313687A (zh) 2013-04-01
MY180618A (en) 2020-12-03
US10463663B2 (en) 2019-11-05
US11129828B2 (en) 2021-09-28
ME02319B (me) 2016-06-20
PT2748149E (pt) 2016-02-04
AR127309A2 (es) 2024-01-10
DK2748149T3 (en) 2016-01-25
TWI546289B (zh) 2016-08-21
EP2748149B9 (en) 2017-11-15
ES2559631T3 (es) 2016-02-15
JO3115B1 (ar) 2017-09-20
RS54515B9 (sr) 2020-12-31
CN103748079A (zh) 2014-04-23
DK2748149T5 (en) 2017-04-24
CY1117105T1 (el) 2017-04-05
PL2748149T3 (pl) 2016-04-29
ZA201400153B (en) 2015-12-23
NZ620239A (en) 2015-10-30
HK1194072A1 (en) 2014-10-10
CO6910197A2 (es) 2014-03-31
BR112014003906A2 (pt) 2017-03-14
PH12014500405A1 (en) 2014-04-07
CN103748079B (zh) 2016-03-16
AU2012298335A1 (en) 2014-01-30
US9290456B2 (en) 2016-03-22
US20180177780A1 (en) 2018-06-28
US20220008416A1 (en) 2022-01-13
CA2846204A1 (en) 2013-02-28
AU2012298335B2 (en) 2017-06-01
HUE026691T2 (hu) 2016-07-28
IL230143A0 (en) 2014-03-06
EA024956B1 (ru) 2016-11-30
AP2014007512A0 (en) 2014-03-31
HRP20151310T1 (xx) 2016-01-01
HRP20151310T2 (hr) 2018-03-23
CA2846204C (en) 2021-04-27
MX2014000783A (es) 2014-04-14
KR101961851B1 (ko) 2019-03-26
PE20141208A1 (es) 2014-09-19
US20200121678A1 (en) 2020-04-23
US12186313B2 (en) 2025-01-07
US9931340B2 (en) 2018-04-03
ES2559631T9 (es) 2018-03-13
RS54515B1 (sr) 2016-06-30
DOP2014000036A (es) 2014-06-30
GEP20156372B (en) 2015-09-25
KR20140054297A (ko) 2014-05-08
SMT201600023B (it) 2016-02-25
UY34280A (es) 2012-10-31
EP2748149A1 (en) 2014-07-02
EP2748149B1 (en) 2015-10-21

Similar Documents

Publication Publication Date Title
CL2014000395A1 (es) Compuestos derivados de piridazinona sustituida; compuesto intermediario; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de la esquizofrenia, trastorno esquizoafectivo, trastornos cognitivos o dolor.
CL2013003372A1 (es) Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
MX2013004307A (es) Derivados de arilamida como bloqueadores de ttx-s.
CL2015001358A1 (es) Potenciadores del cftr deuterados
BR112015003376A8 (pt) composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e usos de quantidade eficiente de composto ou sal farmaceuticamente aceitável do mesmo ou composição farmacêutica
PT2935303T (pt) 4'-fluoro-nucleósidos, 4'-fluoro-nucleótidos e seus análogos para o tratamento de hcv
DK2504005T3 (da) Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
WO2014106238A8 (en) Heterocyclic compounds and methods of use thereof
HRP20180678T1 (hr) Spojevi [1,2,4]triazol[1,5-c]kinazolin-5-amina supstituirani s heterobiciklom pogodni za liječenje ili prevenciju poremećaja središnjeg živčanog sustava
BR112014021531A2 (pt) composto, composição farmacêutica e usos dos mesmos
CL2012003722A1 (es) Compuestos derivados del acido naf-2-ilacetico; composicion farmaceutica; y uso para el tratamiento del sida.
CL2014001752A1 (es) Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras.
HK1213264A1 (zh) 经取代的苯化合物
CL2015003444A1 (es) Compuestos de 3,4 dihidroisoquinolin-2(1h)-ilo
CL2013001654A1 (es) Compuestos derivados de 6-amino-2-fenilamino-1h-bencimidazol-5-carboxamida; composicion farmaceutica; y su uso en el tratamiento y/o prevencion de las enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
HUE053113T2 (hu) Bardoxolon-metil 2,2-difluorpropionamid-származéka, annak gyógyszerkészítményei és polimorfjai bizonyos betegségek kezelésében történõ alkalmazásra
CL2014002557A1 (es) Compuestos bicíclicos de pirazinona; procedimiento de preparacion; composicion farmaceutica; kit; y uso en el tratamiento y/o prevencion de enfermedades cardiovasculares, cancer, entre otras.
CL2008001025A1 (es) Compuestos derivados de pirimido[5,4-d]pirimidina-2,4,6,8-tetraona; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como trastorno metabolico, dislipidemia y cancer.
EP2964222A4 (en) COMPOUNDS FOR INHIBITING THE REPEATING ACTIVITY OF A LEUKINARY KINASEENZYME
MX366308B (es) Derivados de amida como bloqueadores de ttx-s.
HK1206028A1 (en) Phenicol antibacterials
DK3040336T3 (da) Forbindelser til brug i behandling af TYK2 Kinase-medierede tilstande
MX360323B (es) Derivados de pirrolopiridinona como bloqueadores de ttx-s.
EP2964220A4 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
ZA201401678B (en) Novel distributed 3,4-diamino-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases